Drug intelligence / Profile preview

levoxiracetam

Development stage: Phase 3
Lead developer: UCB
Modality: Small Molecules
Administration: Oral, Intravenous, Rectal, Subcutaneous, Nasogastric/gastrostomy Tube

Overview

Levoxiracetam is an investigational drug currently undergoing clinical evaluation. It is being studied for its potential effects on memory and cognitive impairment in patients with traumatic brain injury. Specific details regarding its mechanism of action, chemical structure, or primary developer are not publicly available from the provided context or general search results.

Brand names: Youke
Other names: 4-hydroxy-2-oxo-1-pyrrolidineacetamide (S-enantiomer)(S)-oxiracetam

Targets

SV2A (Synaptic vesicle glycoprotein 2A)SV2B (Synaptic vesicle glycoprotein 2B)

Beyond the preview

Go deeper on levoxiracetam.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on levoxiracetam.

Explore the full profile